INGNInogen, Inc.

INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.

IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.

On August 6, Inogen (NASDAQ:INGN) reported second-quarter results that captured the company’s split personality right now. International sales keep compounding, new products are finding buyers, and profitability is improving. But the US business is still losing ground to a structural shift in how patients get oxygen therapy, and that weakness was enough to push full-year […]

International sales surged 14.8% as new product categories expanded the addressable market.

INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.

Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.

INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.

Moby summary of Inogen, Inc.'s Q2 2026 earnings call

Despite lowering full-year revenue guidance, Inogen raises adjusted EBITDA outlook on robust international sales and successful new product launches.

Inogen (NASDAQ:INGN) reported second-quarter 2026 revenue of $95.1 million, up 3% from a year earlier, as international growth, portable oxygen concentrator demand and contributions from newer products offset continued pressure in its U.S. direct-to-consumer business. The company lowered its full-y

Inogen (INGN) delivered earnings and revenue surprises of +17.65% and +0.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?